Lee Haewon, Saffarian Mathew, Babaria Vivek, McCormick Zachary L
University of California, San Diego, USA.
Department of Orthopedic Surgery, San Diego, CA, USA.
Interv Pain Med. 2022 May 6;1(2):100090. doi: 10.1016/j.inpm.2022.100090. eCollection 2022 Jun.
This series of FactFinders presents a brief summary of the evidence and outlines recommendations regarding the safety of anticoagulant and antiplatelet agents for cervical medial branch blocks and cervical medial branch radiofrequency neurotomy. The evidence in support of the following facts is presented: (1) In patients maintained on therapeutic anticoagulant (AC) and/or antiplatelet (AP) therapy, for whom cervical medial branch blocks (CMBBs) are being considered, there is strong evidence to guide decisions on continuing or discontinuing these AC/AP agents in preparation for the procedure. (2) Therapeutic anticoagulation (AC) and antiplatelet (APT) agents should be discontinued prior to cervical medial branch radiofrequency neurotomy (CMBRFN) due to serious hemorrhagic risks.
本系列《事实发现者》简要总结了证据，并概述了关于抗凝剂和抗血小板药物用于颈椎内侧支阻滞及颈椎内侧支射频神经切断术安全性的建议。以下是支持这些事实的证据：（1）对于正在接受治疗性抗凝（AC）和/或抗血小板（AP）治疗且考虑进行颈椎内侧支阻滞（CMBB）的患者，有充分证据可指导在术前决定继续或停用这些AC/AP药物。（2）由于存在严重出血风险，在进行颈椎内侧支射频神经切断术（CMBRFN）之前应停用治疗性抗凝（AC）和抗血小板（APT）药物。
